PURPOSE: Lung adenocarcinoma is, at present, the most common malignancy in the world and its overall 5-year survival rate is disappointed, because most of the patients are diagnosed at advanced stage. Early diagnosis may improve the prognosis of patients with lung adenocarcinoma. Surface-Enhanced Laser Desorption and Ionization Mass Spectrometry (SELDI) is one of the currently used techniques to identify biomarkers for cancers. This study explored the application of serum SELDI proteomic patterns to distinguish lung adenocarcinoma patients from healthy individuals.
METHODS: In an attempt to improve on current approaches to the serological diagnosis of lung adenocarcinoma, we analyzed serum samples from patients with and without lung adenocarcinoma using surface-enhanced laser desorption and ionization (SELDI) protein chip mass spectrometry. Using a case-control study design, serum samples from 71 patients with surgically resectable lung adenocarcinoma were matched samples from 71 age- and sex-matched healthy controls. The spectra were generated on weak action exchange (WCX2) chips, and protein peaks clustering and classification analyses were made using Ciphergen Biomarker Wizard and Biomarker Pattern software, respectively.
RESULTS: Among the peaks identified by SELDI, the 5 most discriminating protein peaks at 4047.79±1.60, 4203.99±1.91, 4959.81±2.13, 5329.30±2.55 and 7760.12±4.11could differentiate patients with lung adenocarcinoma from healthy controls with sensitivity of 90.41%, 78.08%, 50.68%, 57.53% , 72.60% and specificity of 97.06%, 93.44%, 71.15%, 76.36%, 94.92% when the critical point was 2.5.
CONCLUSION: SELDI profiling of serum can be used to accurately differentiate patients with lung adenocarcinoma from healthy controls.
CLINICAL IMPLICATIONS: SELDI profiling of serum and may be a potential tool for the screening of lung adenocarcinoma with attractive value for the correct clinic decision.
DISCLOSURE: Xiaoyang Luo, None.